[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-stenosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,42,76,117,151,175,198,230,259,286,315,342,363,385,406,436,467,494,517,541,566,591],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100464548","ossdsign-spine-registry-study-propel-100464548",false,"NCT05329129","OssDsign® Spine Registry Study (\"Propel\")","PROSPECTIVE OBSERVATIONAL SPINE FUSION REGISTRY FOR OssDsign® BONE GRAFT SUBSTITUTES IN REAL WORLD CLINICAL PRACTICE","* The patient has been diagnosed as a candidate for spinal fusion surgery for which the surgeon has decided an OssDsign® bone graft is appropriate.\n* The patient is ≥21 years old.\n* The patient is, in the investigator's opinion, psychosocially, mentally, and physically able to fully comply with this protocol, including the post-operative regimen, required follow-up visits, the filling out of required forms, and have the ability to understand and give written informed consent\n* The patient is willing and able to participate in post- operative clinical and radiographic follow up evaluations for 2 years.\n\nExclusion Criteria:\n\n* Patients not meeting all of the inclusion criteria","ALL","21 Years",{"count":19,"type":20},450,"ESTIMATED","OBSERVATIONAL","The purpose of this multi-center, prospective, observational registry is to gather information on the clinical outcomes and real-world use of commercially available bone graft substitutes manufactured by OssDsign® AB, in patients who require spine fusion.",[24,25],"Degenerative Disc Disease","Spinal Stenosis",[27,24,28],"Synthetic bone grafts","Bone fusion","RECRUITING","2026-06-04",{"date":32,"type":33},"2026-06-08","ACTUAL",{"date":35,"type":33},"2022-03-23",{"date":37,"type":20},"2030-04-01",{"name":39,"class":40},"OssDsign","INDUSTRY",15,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100640245","evaluation-of-the-evolution-of-patient-care-within-the-spinal-pathology-department-100640245","NCT07627282","Evaluation of the Evolution of Patient Care Within the Spinal Pathology Department","Evaluation of the Evolution of the Quality of Life of Patients Treated by the Spinal Pathology Department","SPINDATA","Inclusion criteria:\n\n* Patient \\> 18 years old\n* Minor patient, able to accept the data collection, with the consent of the holder(s)\n* Patient consulting for a medical reason involving a spinal pathology in the investigating center (spinal surgery department): Degenerative pathology of the thoracic or lumbar spine; Degenerative pathology of the cervical spine; Deformation of the spine; Urgent traumatic, infectious and tumor pathologies.\n\nExclusion criteria:\n\n* Patient under guardianship or curators,\n* Persons deprived of liberty by judicial or administrative decision,\n* Persons undergoing psychiatric treatment under duress requiring the consent of the legal representative\n* Persons unable to express their consent,\n* Persons under legal protection,\n* Patient not affiliated to a social protection scheme.","18 Years",{"count":52,"type":20},15000,"INTERVENTIONAL",[55],"NA","Spinal conditions are a major public health issue. Their management by surgical treatment is constantly improving and surgical procedures or implantable medical devices are experiencing significant progress. These innovations have not yet all been precisely evaluated but have already led to significant changes in care practices. The primary objective of our study is to describe, via an exhaustive collection of data, the quarterly evolution over 5 years of practices in the management of spinal pathologies.",[25,58,59,60],"SPINAL Fracture","Vertebral Osteomyelitis","Vertebral Metastasis",[62,63,64,65],"spine","care","surgery","evolution","2026-05-29",{"date":30,"type":33},{"date":69,"type":33},"2023-05-25",{"date":71,"type":20},"2031-08",{"name":73,"class":74},"University Hospital, Bordeaux","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":86,"conditions":87,"keywords":95,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100640600","pmcf-study-on-the-effectiveness-and-safety-of-metrosan-spinal-systems-and-bonegraft-filling-materials-100640600","NCT07615491","PMCF Study on the Effectiveness and Safety of METROSAN Spinal Systems and BONEGRAFT Filling Materials","A Prospective, Multi-Center, Observational Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Effectiveness and Safety of METROSAN Spinal Systems and BONEGRAFT Filling Materials Used in Spinal Instrumentation and Fusion Surgery","INFO SPINE","Inclusion Criteria:\n\n* 18 years of age or older.\n* Skeletally mature.\n* Male or female.\n* Undergone spinal surgery (cervical or thoracolumbar) for any indication under current medical practice.\n* Titania® spinal stabilization\u002Ffusion systems and\u002For BONEGRAFT® bone cements or BONEGRAFT® bone graft materials used during the operation.\n* No general health condition contraindicating surgery.\n* No legal restriction (military service, incarceration, or equivalent).\n* Provision of signed and dated Informed Consent Form (ICF)\n\nExclusion Criteria:\n\n* Participation in another interventional clinical investigation\n* Suspected or confirmed pregnancy\n* Morbid obesity\n* Neurological or psychiatric conditions preventing compliance with postoperative care and instructions\n* Active spinal or systemic infection\n* High fever or leukocytosis\n* Severe osteoporosis and\u002For disease affecting bone metabolism\n* Known allergy or hypersensitivity to PEEK, Titanium, or PMMA\n* Congenital abnormality, tumor, or other condition preventing secure implant fixation or likely to shorten implant useful life\n* Inadequate tissue coverage at the operative site\n* Legally restricted individuals (military personnel, prisoners, etc.)",{"count":85,"type":20},561,"This is a prospective, multi-center, observational Post-Market Clinical Follow-Up (PMCF) study designed to collect additional safety and clinical performance data on CE-marked Titania® spinal instrumentation and fusion systems, and Bonegraft® bone filling materials (synthetic bone grafts and bone cements). The study aims to evaluate short-term (12-month) safety and effectiveness, identify previously unknown side effects, monitor defined complications, and assess risks based on real-world evidence in patients undergoing spinal surgery. All investigated products are used within their intended purpose under routine clinical practice.",[88,25,89,90,91,92,93,94],"Degenerative Disc Disease (DDD)","Spondylolisthesis","Spinal Deformities","Spinal Tumors","Spinal Infections","Spinal Trauma","Vertebral Fractures",[96,97,98,99,100,101,102,103,104,105,106,107],"Post-Market Clinical Follow-Up (PMCF)","Spinal Instrumentation","Spinal Fusion","Interbody Fusion","Spinal Stabilization","Spinal Cages","Pedicle Screws","Cervical Plate System","Interspinous Fusion Device","Spinal Implants","Synthetic Bone Graft","Bone Cement","2026-05-22",{"date":66,"type":33},{"date":111,"type":33},"2026-04-27",{"date":113,"type":20},"2028-09-26",{"name":115,"class":40},"Metrosan End. ve Elk. Mek. Cihazlar ve Tibbi Malz. San. Tic. Ltd. Co.",3,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":129,"conditions":130,"keywords":135,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":75},"100614529","cgm-based-glycemic-analysis-after-esi-100614529","NCT07280780","CGM-Based Glycemic Analysis After ESI","Continuous Glucose Monitoring-Based Evaluation of Glycemic Fluctuations Following Epidural Steroid Injections: A Comparative Study by Diabetic Status","CGMSteroid","Inclusion Criteria:\n\n* Adults aged 20 to 60 years.\n* Patients scheduled for cervical or lumbar epidural steroid injection at the pain clinic.\n* Patients capable of understanding and using a Continuous Glucose Monitoring (CGM) device.\n\nExclusion Criteria:\n\n* Patients currently taking or administering steroid medications.\n* Patients with Type 1 Diabetes Mellitus.\n* Patients with Cushing's disease.\n* Patients who have received an epidural steroid injection within the last 3 months.\n* Patients with a known allergy to contrast media.\n* Patients taking anticoagulants or antiplatelet agents.\n* Patients unable to use a Continuous Glucose Monitoring (CGM) device.","20 Years","60 Years",{"count":128,"type":20},36,"The goal of this clinical study is to learn how blood glucose levels change after an epidural steroid injection (ESI) with dexamethasone in adults. It will specifically compare the glycemic response between patients with type 2 diabetes and those without diabetes.\n\nThe main questions it aims to answer are:\n\nDoes the injection cause higher or longer-lasting blood glucose elevation in diabetic patients compared to non-diabetic patients? How do the mean glucose level and Time in Range (TIR) change after the injection in both groups?\n\nResearchers will compare a Type 2 Diabetes group to a Non-Diabetes group to see the differences in glycemic fluctuations using a continuous glucose monitoring (CGM) device.\n\nParticipants will:\n\n* Wear a small CGM sensor on their arm for about 15 days to monitor blood glucose levels continuously\n* Receive an epidural steroid injection containing 5 mg of dexamethasone on Day 3\n* Visit the clinic 3 times (Day 1, Day 3, and Day 15) for sensor attachment, the injection procedure, and data collection",[131,132,133,25,134],"Type 2 Diabetes (T2DM)","Hyperglycemia","Radicular Pain","Intervertebral Disc Herniation",[136,137,138,139,140],"epidural steroid injection","Continuous Glucose Monitoring","Dexamethasone","Glycemic Variability","Time in range","NOT_YET_RECRUITING","2026-04-07",{"date":144,"type":33},"2026-04-09",{"date":146,"type":20},"2026-04-20",{"date":148,"type":20},"2026-12-31",{"name":150,"class":74},"Korea University Anam Hospital",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":53,"phases":159,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":75},"100549778","phase-1-novel-soluble-epoxide-hydrolase-inhibitor-for-neuropathic-pain-in-patients-with-spinal-cord-injury-100549778","NCT06438471","Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury","Development of a Novel Soluble Epoxide Hydrolase Inhibitor as a Strategy for Treating Neuropathic Pain in Patients With SCI","Inclusion Criteria:\n\nEach subject must meet all of the following criteria to be enrolled in this study:\n\n1. Male and female subjects must be 18 and older.\n2. Subjects must be willing to provide written informed consent to participate in the study.\n3. Subjects must be able to provide own transportation to study site every day for the duration of the study.\n4. Subjects with either a traumatic or a non-traumatic SCI may be eligible to enroll in this study. For subjects with complete or incomplete traumatic spinal cord injuries (tSCI), or complete non-traumatic spinal cord injury: Subjects must have a complete or incomplete T6 or below tSCI, or complete non-traumatic SCI of at least 12 months duration, with below-level neuropathic pain identified by the International Spinal Cord Injury Pain (ISCIP) classification criteria. Importantly, subjects must not be ventilator-dependent as detailed in Exclusion Criteria 1. For subjects with degenerative partial spinal cord injuries (pSCI): Subjects must have an incomplete, non-traumatic, SCI at any level secondary to degenerative spinal disorders such as disc degeneration, spinal stenosis, or spondylosis, with associated chronic neuropathic pain. The injury and the associated pain must be of at least 12 months duration. Neuropathic pain should meet the ISCIP classification criteria. Importantly, subjects must not be ventilator-dependent as detailed in Exclusion Criteria 1.\n5. Subjects must have completed a minimum of 6 of the 7 daily assessments for average and worst daily pain prior to final screening, using an 11-point numerical rating scale (NRS) for average daily pain intensity, and the arithmetic average daily SCI neuropathic pain score must be ≥4 and ≤9, with a standard deviation less than or equal to 1.2. Daily pain assessment screenings will be done over the phone with the study coordinator after informed consent is obtained.\n6. Subjects must have failed at least 2 classes of medications for their neuropathic pain due to SCI (classes may include antidepressants, antiepileptics, opioids, anti-inflammatories, topical treatments, etc.).\n7. Subjects must be in overall stable condition, as determined by pre-study medical history, physical examination, clinical laboratory tests, and 12 lead ECG measurements\n8. Subjects must have normal or not clinically significant clinical laboratory test results, as determined by the study investigator, including coagulation panel, blood cell counts, comprehensive metabolic panel analytes, and creatinine clearance (60 cm3\u002Fmin or greater). Clinical laboratory tests results that are consistent with known, stable comorbidities will be allowed as long as the comorbidities do not represent an exclusion criteria per se.\n9. Subjects must have a negative screening for HIV, Hepatitis C, and Hepatitis B within 30 days of randomization.\n10. Subjects must have a normal hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes screening study.\n11. Subjects must have a negative urinary drug screen (UDS) for illicit drugs (marihuana\u002FTHC are allowed) and serum ethanol level \\\u003C80 mg\u002FdL.\n12. Male subjects who are not surgically sterile (vasectomized) and their female sexual partners must agree to use contraception during the study period and for 2 months afterward.\n13. Male subjects must not donate sperm during the study and for 12 months after receiving the last dose of study drug.\n14. Female subjects must be non-pregnant, non-lactating, and either postmenopausal for at least 1 year, or surgically sterile (bilateral tubal ligation ('clipping or tying tubes' or hysterectomy) for at least 3 months, or they must agree to use two forms of highly effective contraception method (less than 1 pregnancy per 100 people using the method for one year), from 28 days and\u002For their last confirmed menstrual period prior to study enrollment (whichever is longer) until 2 months after clinic discharge. Postmenopausal status will be defined as follow: minimum 1 year; amenorrhea duration of 12 consecutive months and a serum FSH value \\>40 IU\u002FL; postmenopausal status must be confirmed by an FSH test at Screening). Highly effective contraception methods include: Intra-uterine device (IUD) containing either copper or levonorgestrel (e.g., Mirena®), and\u002For barrier methods of contraception, including condoms (external or internal) and diaphragm ('cap'). Hormonal methods of contraception (with the exception of hormonal IUD) are not permitted within this study. Female participants will refrain from using hormonal contraceptives for at least 28 days prior to study entry until the end of the study period. Participants\u002FParticipant's partner(s) must also use a barrier form of contraception, from the first dose of study drug through until 2 months after the last dose. For all females of childbearing potential, the pregnancy test result must be negative at Screening and Pre-Study Baseline (Day -1).\n15. Subjects must be able to speak, read, and understand English sufficiently to allow comprehension and completion of all study assessments.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria will be excluded from the study:\n\n1. Ventilator-dependent subjects, with the exception of nocturnal use of CPAP or BiPAP.\n2. Subjects with pain that is not present every day (chronic) or where the pain description does not have a classic neuropathic phenotype.\n3. Subjects with other chronic neuropathic pain conditions, including painful diabetic neuropathy, HIV-associated neuropathic pain, chemotherapy or ethanol-associated neuropathy.\n4. Subjects with other pain syndromes that may confound assessment or self-evaluation of the SCI neuropathic pain.\n5. Subjects with only negative symptoms, defined as numbness without clear evidence of spontaneous pain, either constant or episodic.\n6. Non-opioid pain medications will be allowed if at a fixed stable dose for more than 1 month prior to Screening with no anticipation of the dose changing during the study, and if they do not interfere with the subject's ability to rate pain as per Investigator's discretion. Allowed non-opioid medications include gabapentin, pregabalin, duloxetine, acetaminophen, ibuprofen, celecoxib, meloxicam, other antidepressants including amitriptyline and other antiepileptics, as well as topical capsaicin and topical lidocaine.\n7. Subjects using opioid medications will be required to be on a dose of 60 morphine milligrams equivalents (MME) per day or less, and with a stable dose for at least four (4) weeks prior to consent, with no anticipation of dose changing during the study.\n8. Subjects with active Hepatitis A, Hepatitis B and\u002For Hepatitis C.\n9. Subjects with any clinically unstable or significant cardiovascular (including acute coronary syndrome within the prior year to Screening), renal, hepatic, respiratory, gastrointestinal, hematological, endocrine, or infectious disease (including HIV infection).\n10. Subjects with clinically significant abnormalities on screening vital signs, laboratory tests, and\u002For ECG. Subjects with poor venous access will also be excluded.\n11. Subjects with a history of disorders of the hypothalamic-pituitary-adrenal axis, including adrenal insufficiency and Cushing's, or with a history of disorders of the hypothalamic-pituitary-gonadal axis, including hypogonadism.\n12. Subjects who have used any topical, oral, or intravenous exogenous corticosteroids within 12 weeks and\u002For intra-articular exogenous corticosteroids within 6 months prior to the start of the trial, or who plan on using them during the study.\n13. Subjects who have used fludrocortisone or exogenous testosterone products within 12 weeks prior to the start of the trial or who plan on using them during the study.\n14. Subjects who have used (within 14 of randomization) or plan on using during the duration of the study any renin-angiotensin system (RAS)-acting drugs (including angiotensin-receptor blockers, or ARBs; angiotensin-converting enzyme inhibitors, or ACE-inhibitors; and direct renin inhibitors) or mineralocorticoid receptor antagonists (such as spironolactone and eplerenone)\n15. Subjects who have used chemotherapy agents, or who have a personal history of cancer or cancer in first degree relatives suggestive of elevated cancer risk, other than nonmetastatic skin cancer that has been completely excised, within 5 years prior to Screening.\n16. Subjects with a history of bacterial, fungal, or viral infection requiring treatment with antibiotics, antifungal agents, or antivirals within 1 month prior to randomization.\n17. Subjects who have used (within 14 days of randomization) or plan on using during the duration of the study any prescription or over-the-counter drugs that are moderate-strong CYP3A4 inducers or inhibitors.\n18. Subjects who have used (within 14 days of randomization) or plan on using during the duration of the study any dietary aids, supplements, or foods that are moderate-strong CYP3A4 inhibitors (e.g., grapefruit juice).\n19. Subjects with difficulty in swallowing oral medications.\n20. Subjects with serious psychosocial comorbidities as determined by the Investigator.\n21. Subjects with current cognitive or major psychiatric disorders, or any other condition that could interfere with compliance with study procedures.\n22. Subjects with a positive drug or alcohol test (\\>80 mg\u002FdL) during Screening and\u002For admission (a positive THC test will be allowed as long as it consists of minimal social use, per discretion of Investigator), or with a recent history of binge drinking within 1 week of randomization.\n23. Subjects who have used any other investigational drug within 1 month prior to enrollment. If the investigational drug is known to have a long half-life, a longer washout period will be done.\n24. Subjects with a presence or history of active gastrointestinal disorder, including esophageal or gastroduodenal ulceration, or renal, hepatic, or coagulant disorder within 1 month prior to enrollment.\n25. Subjects with a family history of significant cardiac disease (i.e., sudden death in first degree relative; myocardial infarction before the age of 50).\n26. Subjects with confirmed COVID-19, or suspected COVID-19 (e.g., developed symptoms of a respiratory infection such as cough, sore throat, shortness of breath, or fever, but did not get tested for COVID 19) within 30 days of randomization.\n27. Subjects who have received a COVID-19 vaccine within 30 days of randomization or are planning on receiving it during the study duration.\n28. Exclude subjects with spinal cord injury at T6 or higher with a history of neurogenic bladder.\n29. Exclude subjects with documented autonomic dysreflexia (AD) or a history of episodes consistent with undiagnosed AD as determined by an experienced clinician.",{"count":128,"type":20},[160],"PHASE1","The goal of this clinical trial is to evaluate safety and tolerability of multiple oral doses of EC5026 in male and female patients with neuropathic pain due to traumatic or non-traumatic (degenerative) spinal cord injury. The main question it aims to answer is whether EC5026 is safe and well tolerated in SCI patients with neuropathic pain. In addition, this trial will also study the effects of EC5026 on pain.\n\nResearchers will compare EC5026 to placebo.\n\nParticipants will be asked to:\n\n* Take EC5026 or placebo in a masked fashion, once daily, for 14 consecutive days.\n* Undergo physical exams, vital signs assessments, ECGs, and blood draws\n* Complete assessments of pain, sleep, functional status, and perception of change",[163,164,24,25,165],"Spinal Cord Injuries","Neuropathic Pain","Spondylosis","2026-02-13",{"date":168,"type":33},"2026-02-17",{"date":170,"type":20},"2026-02-28",{"date":172,"type":20},"2027-06",{"name":174,"class":40},"EicOsis Human Health Inc.",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":53,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":75},"100619730","quadro-iliac-vs-thoracolumbar-interfascial-plane-block-for-analgesia-after-single-level-lumbar-disc-surgery-100619730","NCT07348419","Quadro-Iliac vs Thoracolumbar Interfascial Plane Block for Analgesia After Single-Level Lumbar Disc Surgery","Comparison of the Postoperative Analgesic Efficacy of the Quadro-Iliac Plane Block and the Classical Thoracolumbar Interfascial Plane Block in Single-Level Lumbar Disc Surgery: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18-70 years,\n* Classified as ASA physical status I-III,\n* Scheduled to undergo single-level lumbar spinal surgery under general anesthesia\n* Who agree to participate in the study by providing written informed consent\n\nExclusion Criteria:\n\n* History of bleeding diathesis or current anticoagulant therapy\n* Known allergy or hypersensitivity to local anesthetics or opioid medications\n* Infection at the planned block injection site\n* Previous lumbar spine surgery\n* History of gabapentinoid or corticosteroid use within the last 3 weeks\n* Inability to use a patient-controlled analgesia (PCA) device\n* Suspected pregnancy, confirmed pregnancy, or breastfeeding\n* Refusal to undergo the procedure or to participate in the study","70 Years",{"count":184,"type":20},70,[55],"The investigators aim to compare the postoperative analgesic efficacy of the classical thoracolumbar interfascial plane block and the Quadro-iliac plane block for postoperative analgesia management after lumbar disc surgery.",[188,25],"Acute Pain","2026-02-02",{"date":191,"type":33},"2026-02-03",{"date":193,"type":33},"2026-01-06",{"date":195,"type":20},"2026-07-30",{"name":197,"class":74},"Samsun University",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":205,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":53,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":229},"100460304","necessity-of-fusion-following-decompression-surgery-in-patients-with-single-level-lumbar-stenosis-100460304","NCT05273879","Necessity of Fusion Following Decompression Surgery in Patients With Single-level Lumbar Stenosis","Necessity of Fusion Following Decompression Surgery in Patients With Single-level Lumbar Stenosis: Study Protocol for an Open-label Multicenter Non-inferiority Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* age of patients from 45 to 75 years;\n* stenosis C or D according to Shizas et al. according to MRI at the level of L2-L3, L3-L4, L4-L5 or L5-S1;\n* clinical manifestations of lumbar stenosis (neurogenic claudication syndrome and\u002For radiculopathy);\n* lack of effect from conservative therapy within 3 months;\n* Informed consent to take part in the study.\n\nExclusion Criteria:\n\n* spondylolisthesis more than 3 mm;\n* spinal instability according to functional radiography;\n* sagittal imbalance (type 4 according to C. Barrey);\n* bone density of the vertebrae at the level of the operation is less than 100 HU;\n* clinically significant spinal stenosis at 2 or more levels;\n* previously performed surgeries on the spine;\n* risk of anesthesia 4 or 5 according to ASA;\n* inability to take part in control examinations within 2 years after the operation;\n* participation in other clinical trials related to surgical or conservative treatment of diseases of the spine.","45 Years","75 Years",{"count":208,"type":20},86,[55],"Long-term clinical results of two methods of surgical treatment (spinal decompression with or without fusion) in patients with single-level lumbar stenosis will be compared. A clear framework for surgical treatment methods and standardized postoperative rehabilitation treatment will be set to obtain the maximum homogeneity of the patient groups.\n\nThis trial should provide the first level of evidence for the need for spinal fusion in patients with single-level lumbar stenosis, subject to the high homogeneous comparison groups. Additional results will allow comparing the economic aspects of different surgical treatments for 2 years after surgery.",[212,25,98],"Lumbar Spinal Stenosis",[214,215,216,217,218],"lumbar spine","lumbar fusion","laminotomy","decompression without fusion","lumbar stenosis","2025-12-11",{"date":221,"type":33},"2025-12-18",{"date":223,"type":33},"2022-04-01",{"date":225,"type":20},"2026-12-30",{"name":227,"class":228},"Sklifosovsky Institute of Emergency Care","OTHER_GOV",2,{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":53,"phases":240,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100610842","cytokines-neuroplasticity-modulators-and-biomarkers-in-spinal-canal-stenosis-and-endoscopic-decompression-100610842","NCT07232836","Cytokines, Neuroplasticity Modulators, and Biomarkers in Spinal Canal Stenosis and Endoscopic Decompression","The Role of Cytokines and Neuroplasticity Modulators in the Development of Spinal Canal Stenosis and the Identification of Biomarkers for the Biochemical Evaluation of Treatment in Patients Undergoing Endoscopic Spinal Canal Decompression","Inclusion Criteria for the experimental group:\n\n1. Spinal stenosis in the lumbar spine with a referral for surgical treatment using endoscopic spinal decompression.\n2. Age: 40-90 years.\n3. Current MRI results.\n4. Consent to participate in the study.\n\nInclusion Criteria for the control no spinal stenosis group:\n\n1. Intervertebral disc herniation in the lumbar spine with a referral for surgical treatment using endoscopic discectomy.\n2. Age: 18-40 years.\n3. Current MRI results.\n4. Consent to participate in the study.\n\nExclusion Criteria:\n\nHistory of:\n\n* rheumatoid arthritis of the intervertebral joints,\n* joint pain located elsewhere if it is more severe than the pain caused by stenosis,\n* pathologies and\u002For medications that may disturb the balance between pro- and anti-inflammatory factors (e.g. inflammatory diseases, rheumatoid arthritis, ankylosing spondylitis, acute infection),\n* uncontrolled diabetes, poorly controlled hypertension, clinically significant liver function impairment, acute coronary event, unstable angina pectoris, symptoms of heart failure, pacemaker implantation,\n* neurological diseases within the last 6 months,\n* previous spine surgery at the lumbar level,\n* mechanical injuries to the spine after an accident,\n* advanced osteoporosis,\n* pregnancy, lactation.","90 Years",{"count":239,"type":20},100,[55],"Research Rationale and Study Design Lumbar spinal stenosis (LSS) is a common degenerative musculoskeletal disorder characterized by narrowing of the spinal canal, often leading to pain and disability. One of the primary contributors to this condition is hypertrophy (thickening) of the ligamentum flavum (LF), along with facet joint degeneration, intervertebral disc herniation, and ligament ossification. However, the pathophysiological mechanisms behind these changes remain incompletely understood.\n\nHistological changes in hypertrophied LF include fibrocartilaginous metaplasia, type II collagen proliferation, ossification, calcium crystal deposition, and degeneration of elastic and collagen fibers. Both mechanical stress and inflammatory processes, particularly macrophage infiltration, are considered key contributors to degeneration, especially in the aging population. Yet, inflammation linked to systemic metabolic disorders-such as obesity and sarcopenia-may also significantly influence the degeneration of spinal structures.\n\nMetabolic Inflammation and the Role of Adipokines Recent research has highlighted the role of adipokines in the pathogenesis of degenerative spinal and joint diseases. Disrupted lipid metabolism and chronic low-grade inflammation contribute to tissue remodeling, extracellular matrix (ECM) degradation, and ectopic fat deposition in spinal structures.\n\nEpidural fat, normally present in the spinal canal, can become inflamed and secrete pro-inflammatory cytokines, potentially affecting adjacent tissues such as muscles and ligaments. Conditions like spinal epidural lipomatosis, which is associated with obesity, exemplify this pathological mechanism.\n\nWhile adipokines like leptin and visfatin have been previously associated with LF ossification and degeneration, the presence and role of others-such as adipsin, vaspin, resistin, lipocalin-2, progranulin, chemerin, omentin-1, and GDF-15-have not yet been studied in LF or epidural fat. Given their known effects on inflammation and ECM remodeling, these molecules are strong candidates for involvement in spinal canal narrowing.\n\nResearch Hypotheses and Objectives\n\nThis study hypothesizes that adipose tissue-derived cytokines, particularly from epidural fat, contribute to LF degeneration and LSS through inflammatory and metabolic signaling. The main research objectives are to:\n\n1. Identify differences in biomarker concentrations in LF, paraspinal muscle, and epidural fat from patients with and without LSS.\n2. Determine correlations between tissue and blood biomarker levels and clinical parameters such as pain, disability, and body mass.\n3. Select potential biomarkers for monitoring surgical outcomes of spinal decompression.\n4. Identify cytokines that modulate LF inflammation and metabolism.\n5. Evaluate the direct effects of adipokines on LF cell behavior in vitro. Study Design and Methods\n\n   Study population:\n\n   • 100 patients undergoing lumbar spine surgery at the Orthopaedic-Rehabilitation Clinical Hospital in Poznań:\n\n   o 50 with LSS (ages 40-90)\n   * 50 with disc herniation only (ages 18-40; control group)\n\n   Tissue collection (intraoperative):\n\n   • Ligamentum flavum\n\n   • Paraspinal muscles\n\n   • Epidural adipose tissue\n\n   Blood samples:\n\n   • Collected from all participants:\n\n   o Within 48 hours before surgery\n\n   o Two months post-surgery\n\n   Clinical assessments:\n\n   • Disability and pain scales\n   * Preoperative MRI scans\n\n   Laboratory analysis:\n\n   • Molecular testing:\n   * mRNA expression of selected cytokines and adipokines using PCR\n   * Protein levels determined via ELISA in both serum and tissue homogenates • Cell culture studies:\n   * One-third of collected tissue is used to establish primary cell cultures from LF, paraspinal muscles, and epidural fat\n   * Cells will be stimulated with conditioned media from epidural fat and with selected recombinant cytokines (e.g., vaspin, lipocalin-2, GDF-15)\n   * Experiments will assess the gene and protein expression of key molecules involved in inflammation, ECM remodeling, bone metabolism, fibrosis, and matrix degradation.\n\n   The goal is to clarify the local and systemic roles of adipokines and inflammation in the pathogenesis of LF hypertrophy and LSS. This knowledge may aid in identifying biomarkers for disease progression and therapeutic targets for non-surgical interventions in the future.",[25,243],"Ligamentum Flavum Hypertrophy",[245,246,247,248,249],"adipokines","biomarkers","endoscopic spinal canal decompression","inflammation","epidural adipose tissue","2025-11-15",{"date":252,"type":33},"2025-11-18",{"date":254,"type":20},"2025-11-17",{"date":256,"type":20},"2030-12-31",{"name":258,"class":74},"Poznan University of Physical Education",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":266,"enrollmentInfo":267,"targetDuration":269,"studyType":21,"phases":4,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":75},"100467390","thoracic-lumbar-arthrodesis--implanet-jazz-100467390","NCT05366140","Thoracic-Lumbar Arthrodesis- Implanet Jazz","Prospective Follow-up of Patients Undergoing Instrumented Thoracic and Lumbar Arthrodesis Supplemented by the Implanet Jazz System TM.","Inclusion Criteria:\n\n* Male and female patients, 18 years of age and older\n* Qualified candidate for hybrid thoracolumbar fixation with the Implanet Jazz System TM during arthrodesis surgery.\n\nExclusion Criteria:\n\n* Individuals who have not yet reached the age of 18.","100 Years",{"count":268,"type":20},300,"5 Years","Establish a data repository of patients who have undergone single, two-, or three-level lumbar instrumented arthrodesis procedures supplemented by the Implanet Jazz System.",[89,25,272],"Degenerative Disease",[274,275,276],"Thoracic-Lumbar Arthrodesis","Spinal fusion","back pain","2025-10-23",{"date":279,"type":33},"2025-10-27",{"date":281,"type":33},"2022-02-03",{"date":283,"type":20},"2028-09",{"name":285,"class":74},"Francis Farhadi",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":293,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":53,"phases":297,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":75},"100599098","effects-of-maitland-and-mulligan-spinal-mobilizations-along-with-canal-enlargement-exercises-in-lumbar-spinal-stenosis-100599098","NCT07080073","Effects of Maitland and Mulligan Spinal Mobilizations Along With Canal Enlargement Exercises in Lumbar Spinal Stenosis","Comparative Effects of Maitland and Mulligan Spinal Mobilizations Along With Canal Enlargement Exercises in Patients of Lumbar Spinal Stenosis","Inclusion Criteria:\n\n* Age group between 25-40 years\n\n  * Both males and females will be included\n  * Patient with low back pain along with unilateral radiating symptoms\n  * Having symptoms from at least 3 months with pain severity not more than 7 on NPRS\n  * Diagnosed case of slipped disc or herniation causing spinal stenosis, confirmed by physical examination and\u002For MRI.\n\nExclusion Criteria:\n\n* Chronic inflammatory or infectious disease, neoplasm, hematological disorders, traumatic vertebral injuries, Spondylitis\n\n  * Any concurrent major disease like renal failure, diabetes, cancer, tumor.\n  * Low back pain with bilateral radiating symptoms.\n  * Pregnancy\n  * Cognitive alteration and non-co-operative patient\n  * Spinal surgery","25 Years","40 Years",{"count":296,"type":20},38,[55],"This randomised controlled trial will evaluate the comparative effects of Maitland versus Mulligan spinal mobilization techniques, when combined with canal enlargement exercises, in patients with lumbar spinal stenosis (LSS). A total of 38 participants aged 25-40 years with confirmed unilateral LSS will be randomly assigned to receive either Maitland mobilizations or Mulligan mobilizations, along with standard physiotherapy and canal enlargement exercises. The intervention will be administered over three weeks, with four sessions per week. Primary outcomes will include pain intensity (measured by Numeric Pain Rating Scale), disability (Modified Oswestry Disability Index), and symptom severity (Swiss Spinal Stenosis Score), assessed at baseline and post-treatment. This study aims to inform physiotherapy practice by identifying the more effective manual therapy technique for improving functional outcomes in LSS.",[25,300],"Low Back Pain",[302,303,304,305],"Manual Therapy","Canal Enlargement Exercises","Pain","Disability","2025-07-14",{"date":308,"type":33},"2025-07-23",{"date":310,"type":20},"2025-07",{"date":312,"type":20},"2025-11-30",{"name":314,"class":74},"Riphah International University",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":323,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":53,"phases":327,"briefSummary":328,"conditions":329,"keywords":330,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":116},"100404882","physical-therapy-vs-surgical-decompression-for-lumbar-spinal-stenosis-100404882","NCT04552145","Physical Therapy vs Surgical Decompression for Lumbar Spinal Stenosis","Physical Therapy Versus Surgical Decompression for Lumbar Spinal Stenosis: A Multicenter Randomized Controlled Trial","PTvsSD","Inclusion Criteria:\n\n* Patients describing intermittent neurogenic claudication when walking and symptoms revealed by flexion of the spine.\n* MRI shows lumbar spinal stenosis in one or two levels measured.\n* The duration of the symptoms is longer than six months\n* The patient is a candidate for surgical treatment\n* The patient is capable of physical exercise\n\nExclusion Criteria:\n\n* Vascular intermittent claudication\n* Lumbar spinal stenosis in more than two levels\n* Previous low back surgery\n* Symptomatic lumbar disc herniation\n* Degenerative scoliosis with Cobbs angle 30 degrees or more\n* Degenerative spondylolisthesis grade 2 or more\n* Spondylolysis with spondylolisthesis\n* Recent osteoporotic fractures in the spine (last 6 month)\n* Severe symptomatic arthrosis in hip or knee\n* Locally advanced or metastatic cancer\n* ASA \\>3\n* Polyneuropathy recognized by neurography\n* Insufficient Norwegian language skills","50 Years","80 Years",{"count":326,"type":20},232,[55],"This is a randomized controlled multicenter trail comparing physical therapy to surgical decompression in patients with lumbar spinal stenosis. The 0-hypothesis is that there is no difference in the efficacy of structured physical therapy compared to surgical decompression.\n\nOur aim is to evaluate if physical therapy can serve as a nonsurgical alternative for patients with LSS, where the severity of symptoms indicates the need of surgical decompression.",[25],[331,332],"Surgery","Physical Therapy Modalities","2025-06-17",{"date":335,"type":33},"2025-06-22",{"date":337,"type":33},"2020-09-01",{"date":339,"type":20},"2027-08-31",{"name":341,"class":74},"Norwegian University of Science and Technology",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":53,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":75},"100525322","pulse-width-modulation-100525322","NCT06120231","Pulse-Width Modulation","Pulse-width Modulation During Pedicle Screw Stimulation","Inclusion Criteria:\n\n* A patient will be eligible for study participation once they have been booked for a surgery involving pedicle screw placement and intraoperative neuromonitoring.\n\nExclusion Criteria:\n\n* The study excludes neonates, minors, pregnant women, prisoners and cognitively impaired patients.",{"count":350,"type":20},50,[55],"The overarching aim of this project is to modulate the pulse-width during stimulation of pedicle screws and record the response thresholds associated with each PWM setting. During this initial phase of the investigation, no further data will be collected.",[98,25],"2025-06-03",{"date":356,"type":33},"2025-06-05",{"date":358,"type":33},"2023-12-01",{"date":360,"type":20},"2027-06-01",{"name":362,"class":74},"Dartmouth-Hitchcock Medical Center",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":266,"enrollmentInfo":369,"targetDuration":4,"studyType":53,"phases":371,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":381,"leadSponsor":383,"locationsCount":75},"100526913","phase-3-effect-of-ketamine-on-intraoperative-motor-evoked-potentials-100526913","NCT06140927","Effect of Ketamine on Intraoperative Motor Evoked Potentials","Inclusion Criteria:\n\n* Adult patients (\\>18 years of age) undergoing posterior spinal fusions.\n\nExclusion Criteria:\n\n* Sensitivity or allergy to ketamine.\n* Schizophrenia or other psychotic conditions\n* Uncontrolled hypertension with systolic blood pressure greater than 180 mmHg\n* Myocardial Infarction\n* Large vascular aneurysms\n* Patients on ketamine as outpatient therapy.",{"count":370,"type":20},20,[372],"PHASE3","The goal of this clinical trial is to learn about the effect of ketamine on intraoperative motor evoked potentials in adult patients undergoing thoracolumbar spinal fusions. Participants will undergo a standard anesthetic. In addition to the standard anesthetic, the patients will be administered increasing doses of ketamine with motor-evoked potentials being measured at each dose, to assess any impacts.",[375,376,25],"Spine Fusion","Spine Tumor","2025-05-05",{"date":379,"type":33},"2025-05-07",{"date":358,"type":33},{"date":382,"type":20},"2026-12-01",{"name":384,"class":74},"University of California, San Francisco",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":405},"100589164","escape--evaluation-of-spinal-conservation-by-endoscopic-procedures-to-avoid-fusion-100589164","NCT06950853","ESCAPE : Evaluation of Spinal Conservation by Endoscopic Procedures to Avoid Fusion","ESCAPE","Inclusion Criteria:\n\n* Patient ≥ 18 years old\n* Patient consulting for a medical reason involving a spinal pathology in the investigating center :\n\nSyndrome adjacent to an old lumbar arthrodesis defined on preoperative radiographs by an antero-posterior translation \\> 3 mm, segmental kyphosis \\> 10° or a disc height reduced by more than 50%, or on preoperative MRI by central stenosis of grade C or D of the Schizas classification or a herniated disc Grade 1 or 2 degenerative spondylolisthesis, i.e. with slippage less than 50% of the depth of the underlying vertebral body.\n\nLumbar stenosis complicating lumbar scoliosis defined by a deformation with rotation of the vertebral bodies on a frontal radiograph (absence of centering of the spinous process between the two pedicles of the vertebra concerned) and a Cobb angle greater than 20° or a rotational dislocation .\n\n\\- Indication for spinal surgery by endoscopy\n\nExclusion Criteria:\n\n* Patient under guardianship or curatorship,\n* Persons deprived of liberty by judicial or administrative decision,\n* Persons undergoing psychiatric treatment under duress requiring the consent of the legal representative\n* Persons unable to express their consent,\n* Persons under legal protection,\n* Patient not affiliated to a social protection scheme.",{"count":393,"type":20},375,"The recent development and expansion of endoscopic surgery has made it possible to offer an alternative to this therapeutic escalation. This method allows decompression procedures to be performed using optimized and minimally destructive surgical approaches, which contributes to preserving the physiological function of the lumbar spine and in particular its stability.\n\nThe main hypothesis of the research is that the use of endoscopic techniques for decompression of the lumbar spine allows a reduction in the indication for lumbar arthrodesis.",[25,89],[62,63,64],"2025-04-22",{"date":399,"type":33},"2025-04-30",{"date":401,"type":33},"2024-02-01",{"date":403,"type":20},"2028-08-13",{"name":73,"class":74},13,{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":53,"phases":416,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":75},"100517995","vertebropexy---randomized-controlled-trial-100517995","NCT06024785","Vertebropexy - Randomized-controlled Trial","Comparison of Ligamentous Fixation Technique (Vertebropexy) Versus Conventional Decompression or Fusion Surgery for Degenerative Lumbar Spinal Disease: A Randomized Controlled Trial","VPRCT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Single-level or two-level lumbar surgery needed\n* Indication for decompression surgery in patients with spinal canal stenosis and additional stable degenerative listhesis (without facet joint effusion ≥ 2mm)\n* Indication for fusion surgery in patients with spinal canal stenosis and additional unstable degenerative listhesis (facet joint effusion ≥ 2mm), in patients with foraminal stenosis and additional degenerative listhesis, and in patients with segment degeneration of the disc\n* Understanding in German language\n\nExclusion criteria:\n\n* Indication for decompression and\u002For fusion surgery in patients with solely disc herniation, fractures, lytic listhesis, tumor\n* Patients undergoing revision surgery for infection\n* Patients undergoing revision surgery on the same level if bony structures have been removed (e.g. prior laminectomy or midline decompression)\n* Patients undergoing revision surgery in case of prior fusion surgery\n* Inability to understand the study for linguistic or cognitive reasons\n* Anticipated clinical follow-up of less than 6 weeks after inclusion\n* Participation in other clinical trials",{"count":415,"type":20},164,[55],"To assess the need for additional fusion surgery versus the risk of a revision surgery in patients with degenerative lumbar spinal disease and to assess efficacy and risk of the ligamentous fixation technique (vertebropexy)",[419,25,420],"Degeneration","Fusion of Spine",[422,423,424,425,426],"degenerative lumbar spinal disease","decompression","fusion","vertebropexy","ligamentous fixation","2025-02-11",{"date":429,"type":33},"2025-02-13",{"date":431,"type":33},"2025-01-16",{"date":433,"type":20},"2028-12",{"name":435,"class":74},"Balgrist University Hospital",{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":16,"minAge":444,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":53,"phases":447,"briefSummary":448,"conditions":449,"keywords":453,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":75},"100462821","preventing-pain-after-surgery-100462821","NCT05306665","PREventing Pain After Surgery","PREventing Pain After Surgery: a Feasibility and Acceptability Study of Acceptance and Commitment Therapy for the Prevention of Chronic Post-surgical Pain (PREPS)","PREPS","Inclusion Criteria:\n\n* scheduled to undergo fusion, discectomy, vertebroplasty, kyphoplasty, or foraminotomy\n* age 22 and older\n* able to communicate fluently in English\n\nExclusion Criteria:\n\n* inability to complete study procedures due to delirium, dementia, psychosis, or other cognitive impairment\n* have a history of severe neurologic movement disorder\n* are pregnant or intent to become pregnant during study\n* have undergone previous spinal surgery\n* have spinal deformity, pseudarthrosis, trauma, infection, or tumor as primary indication for surgery\n* have undergone Acceptance and Commitment Therapy in last 2 years","22 Years",{"count":446,"type":20},140,[55],"The present study aims to adapt and modify a brief presurgical Acceptance and Commitment Therapy (ACT) intervention aimed at preventing the transition to Chronic Post-Surgical Pain (CPSP) and reducing long-term opioid use. Investigators will then assess the acceptability, feasibility, and preliminary efficacy of the finalized intervention to prevent the transition to CPSP and reduce post-surgical opioid use six months following lumbar spine surgery. Finally, investigators will identify psychosocial and psychophysical phenotypes associated with response to this intervention.",[450,25,451,165,89,452],"Pain, Back","Disc Herniation","Back Injuries",[454,331,455,456,457],"Chronic pain","opioid","acceptance and commitment therapy","Prevention","2024-10-25",{"date":460,"type":33},"2024-10-28",{"date":462,"type":33},"2023-01-13",{"date":464,"type":20},"2026-08-01",{"name":466,"class":74},"Brigham and Women's Hospital",{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":11,"sex":16,"minAge":475,"maxAge":476,"enrollmentInfo":477,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":75},"100408660","personalized-spine-study-group-pssg-registry-100408660","NCT04601363","Personalized Spine Study Group (PSSG) Registry","Personalized Spine Study Group (PSSG) Registry of Patients With Personalized Spine Rod Implantation","PSSG","Inclusion Criteria:\n\n* Patient has been\u002F will be operated and instrumented with patient-specific rod or spine hardware (control cohort)\n* Patient able to consent or assent\n\nExclusion Criteria:\n\n* Patient unable to sign an informed consent form\n* Patient unable to complete a self-administered questionnaire\n* Patient is pregnant or planning on becoming pregnant during the duration of their study participation\n* Patient is older than 85\n* Patient is younger than 10","10 Years","85 Years",{"count":478,"type":20},1000,"The primary objective of the study is a data collection initiative. The study will collect clinical and radiographic outcomes of patients implanted with patient specific rods. The secondary objective is to collect clinical and radiographic outcomes of patients with hardware as a control cohort to the patient-specific rods.",[481,24,98,482,483,25,484],"Scoliosis; Adolescence","Kyphoscoliosis","Pseudoarthrosis of Spine","Kyphoses, Scheuermann","2024-10-01",{"date":487,"type":33},"2024-10-03",{"date":489,"type":33},"2020-10-29",{"date":491,"type":20},"2030-04",{"name":493,"class":74},"University of Colorado, Denver",{"id":495,"slug":496,"hasResults":11,"nctId":497,"briefTitle":498,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":11,"sex":16,"minAge":126,"maxAge":4,"enrollmentInfo":501,"targetDuration":503,"studyType":21,"phases":4,"briefSummary":504,"conditions":505,"keywords":506,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":4},"100560457","enhanced-recovery-after-surgery-for-spine-fusion-surgeries-in-the-elderly-100560457","NCT06577389","Enhanced Recovery After Surgery for Spine Fusion Surgeries in the Elderly","ERAS in Spine","Inclusion Criteria:\n\n* elderly patients who received spinal fusion surgeries\n\nExclusion Criteria:\n\n* patients who received non-fusion surgeries",{"count":502,"type":20},1500,"12 Months","elderly patients in our hospital who received spinal fusion surgery after the year 2025 will receive ERAS treatment.",[25],[507],"spine fusion surgery","2024-08-28",{"date":510,"type":33},"2024-08-29",{"date":512,"type":20},"2025-01-01",{"date":514,"type":20},"2028-12-31",{"name":516,"class":74},"Sixth Affiliated Hospital of Xinjiang Medical University",{"id":518,"slug":519,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":11,"sex":16,"minAge":524,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":53,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":75},"100529835","effects-of-cognitive-intervention-therapy-on-postoperative-delirium-100529835","NCT06178939","Effects of Cognitive Intervention Therapy on Postoperative Delirium","Effects of Cognitive Intervention Therapy on Postoperative Delirium in Elderly Non-cardiac Surgical Patients","Inclusion Criteria:\n\n* Elderly patients aged 65 and above.\n* Patients undergoing orthopedic, thoracic, or hepatopancreatobiliary surgery under general anesthesia with an expected surgery duration of 2 hours or more.\n* Patients scheduled for arterial catheterization.\n\nExclusion Criteria:\n\n* Patients with uncontrolled systemic conditions such as diabetes and hypertension.\n* Those with visual impairment.\n* Patients with cognitive impairment based on the MMSE-DS criteria.\n* Individuals experiencing difficulty in communication.\n* Those diagnosed with neurological disorders (such as brain hemorrhage, stroke, brain tumor, dementia, Parkinson's disease, cognitive impairment, depression, etc.).\n* Patients diagnosed with alcohol or substance addiction.","65 Years",{"count":526,"type":20},60,[55],"This study is a prospective, single-center, randomized controlled trial to compare whether applying cognitive intervention therapy before and after surgery in elderly patients aged 65 years or older undergoing non-cardiac surgery can reduce the incidence of postoperative delirium compared to conservative treatment.",[25,451,530,531],"Lung Neoplasms","Carcinoma, Hepatocellular","2023-12-15",{"date":534,"type":33},"2023-12-21",{"date":536,"type":20},"2023-12",{"date":538,"type":20},"2027-10",{"name":540,"class":74},"Yonsei University",{"id":542,"slug":543,"hasResults":11,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":324,"enrollmentInfo":549,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":551,"conditions":552,"keywords":554,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":562,"leadSponsor":564,"locationsCount":75},"100513311","the-spine-promco-study-100513311","NCT05963815","The Spine PROMCO Study","Spine Patient Reported Outcome Measures: a Cohort Observational Study","Spine PROMCO","Inclusion Criteria:\n\n* All patients who are eligible for elective surgery of the lumbar spine.\n* All patients with degenerative disorder of the lumbar spine including: herniated disk, stenosis, discopathy and spondylolisthesis.\n* Patients must be able to fill in the questionnaire online\n* Patients with imaging (Magnetic resonance imaging (MRI)) confirmed lumbar disc herniation, stenosis, discopathy, or listhesis.\n* Elective cases\n* Patients operated with laminectomy, microscopic discectomy, percutaneous transforaminal endoscopic discectomy, and spondylodesis.\n\nExclusion Criteria:\n\n* Patients who cannot speak nor read the Dutch language\n* Patients who are not able to complete the digital questionnaires, according to the including doctor\n* Patients with fractures, primary infections of the spine, or with spinal malignant- cies.\n* Patients in a traumatic setting.",{"count":550,"type":20},4000,"Our primary objective is to design a cohort to determine the treatment outcome of different surgical interventions of the degenerative lumbar spine highlighting the expediency and value of the current surgical treatment program.",[553,89,25],"Lumbar Disc Herniation",[555,556,557],"Patient related outcome measures","Prognosis","Degenerative Spine disease","2023-09-26",{"date":560,"type":33},"2023-09-28",{"date":462,"type":33},{"date":563,"type":20},"2030-01-13",{"name":565,"class":74},"Park Medical centrum",{"id":567,"slug":568,"hasResults":11,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":575,"conditions":576,"keywords":580,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":75},"100228914","the-effect-of-integrated-cam-treatment-in-hospitalized-patients-100228914","NCT02257723","The Effect of Integrated CAM Treatment in Hospitalized Patients","The Effect of Integrated CAM Treatment in Patients Hospitalized at a Korean Medicine Hospital","Inclusion Criteria:\n\n* Patients hospitalized due to spine or joint diseases\n\nExclusion Criteria:\n\n* Main complaint other than back pain, radiating leg pain, neck pain, radiating arm pain, knee pain or shoulder pain\n* Cause of pain non-related to spine, joint or soft tissue; for example, spinal tumors, pregnancy, urolithiasis, etc.\n* Refusal to provide the information needed for clinical research",{"count":574,"type":20},100000,"This study investigates the effect of hospital-based intensive non-surgical treatment in musculoskeletal patients admitted to an integrated hospital that offers both complementary and alternative medicine (CAM) and conventional medicine treatment.",[300,577,578,579,134,25],"Neck Pain","Knee Pain","Shoulder Pain",[581,582,583],"Inpatient care","Complementary and alternative medicine","Integrated medicine",{"date":560,"type":33},{"date":586,"type":33},"2012-01",{"date":588,"type":20},"2040-12",{"name":590,"class":74},"Jaseng Hospital of Korean Medicine",{"id":592,"slug":593,"hasResults":11,"nctId":594,"briefTitle":595,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":11,"sex":16,"minAge":125,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":53,"phases":599,"briefSummary":600,"conditions":601,"keywords":602,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":75},"100353525","vancomycin-powder-combined-with-autogenous-bone-graft-as-a-prevention-for-post-operative-infection-for-spine-surgery-100353525","NCT03883022","Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery","Inclusion Criteria:\n\n* Patients who have instrumented spine fusion surgery due to failed conservative treatment (bed rest, medication, rehabilitation programs) for 3 to 6 months\n* Patients who are willing to sign the surgical permit after the surgeon explains all surgical procedures along with the surgical risks\n* Patients who fully understand the surgical procedures as well as the surgical risks and are willing to sign the surgical permit and the inform consent\n* Patients who agree one more blood withdrawal after operation\n\nExclusion Criteria:\n\n* Patients who agree to accept the spine surgery but do not agree to sign the inform consent\n* Patients who have allergic reaction to vancomycin",{"count":598,"type":20},400,[55],"Deep surgical site infection (DSSI) is one of the most challenging complications for spinal surgeons and can lead to a poor clinical outcome. This ambispective study was designed to examine the effect of vancomycin powder mixed with autogenous bone graft and bone substitute on preventing deep surgical site infection (DSSI) in degenerative lumbar fusion surgeries as well as any interference with bony fusion.",[98,25,89],[603,604,605,606],"Deep surgical site infection","Vancomycin-impregnated bone graft","Spine surgery","Degenerative lumbar disorder","2019-03-18",{"date":609,"type":33},"2019-03-20",{"date":611,"type":33},"2018-09-03",{"date":613,"type":20},"2027-12-31",{"name":615,"class":228},"Taipei Veterans General Hospital, Taiwan"]